

Advancing Care in Lupus Nephritis: EXPLORING THE EVOLVING LANDSCAPE

JOIN US FOR OUR EXHIBITOR SPOTLIGHT AT KIDNEY WEEK 2025

PROGRAM DESCRIPTION:

The treatment landscape for lupus nephritis (LN) continues to evolve, offering clinicians additional tools to help improve outcomes for patients facing this challenging autoimmune disease. Recent advances of therapies are expanding possibilities for patients with active lupus nephritis.¹

In this interactive session, Dr. Appel will provide an in-depth overview of the current unmet needs in lupus nephritis. This presentation will further highlight the chronic inflammation driven by B cells,² the risk of irreversible kidney damage,³ and how evolving clinical guidance—including recent updates from ACR, EULAR, and KDIGO—can inform the use of advanced therapies earlier to help improve patient outcomes.^{1,4,5}

LEARNING OBJECTIVES:

- Highlight the Unmet Needs of Lupus Nephritis Patients
- Understand the Driving Mechanisms of Kidney Damage in Lupus Nephritis
- Discuss the Evolving Treatment Landscape of Advanced Therapies

PRESENTER:



Gerald B. Appel, MD, FASN

Co-Director of Clinical Nephrology
NewYork-Presbyterian Hospital/
Columbia University Medical Center
New York, NY



**EXHIBIT HALL D
THEATER #1**

**GEORGE R. BROWN CONVENTION CENTER
HOUSTON, TX**

NOVEMBER 6, 2025

12:00 PM TO 12:45 PM CST

This event is supported by Genentech.

The Exhibitor Spotlight is not a Continuing Education (CE) activity.

Genentech

A Member of the Roche Group

© 2025 Genentech USA, Inc. All rights reserved.
M-US-00029286(v1.0) 10/25

- Minnesota, Vermont, and Federal Entities (eg, the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (eg, meals) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program
- Please indicate whether you will accept or opt out of Genentech's in-kind benefits (eg, meals) at the program. If you choose to opt out, you may not consume any food or beverage during the program
- For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit [sunshine.gene.com](https://www.sunshine.gene.com))
- The meal value reported may vary by event location and be up to \$150 per person (exceptions may apply)

ACR=American College of Rheumatology; EULAR=European Alliance of Associations for Rheumatology; KDIGO=Kidney Disease: Improving Global Outcomes.

References: 1. Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken)*. 2025;77(9):1045-1065. doi:10.1002/acr.25528 2. Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. *Clin J Am Soc Nephrol*. 2018;13(10):1502-1509. doi:10.2215/CJN.01070118. Published correction appears in *Clin J Am Soc Nephrol*. 2019;14(1):111. doi:10.2215/CJN.12621018 3. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. *Nat Rev Dis Primers*. 2020;6(1):7. doi:10.1038/s41572-019-0141-9 4. Boumpas DT, et al. Presented at EULAR Congress; Barcelona, Spain, June 11-14, 2025. 5. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. *Kidney Int*. 2024;105(suppl 1):S1-S69. doi:10.1016/j.kint.2023.09.002